MUC1 and systemic sclerosis: Stock et al., among 189 patients with systemic sclerosis-associated ILD, also reported that the patients with high baseline KL-6 levels (> 1472 U/mL) showed shorter time to ≥ 15% decline in DLco (p = 0.003) [29].